Diabetes

Soliqua 100/33 is a combination treatment of Lantus and lixisenatide for the treatment of type 2 diabetes.

Contour Next One Blood Glucose Monitoring System features a blood glucose smart meter that connects to the Contour Diabetes app.

Pharmacists improve care for patients in many settings, especially for diabetes.

Pharmacists are slowly changing the way they deliver their services. Previous professional literature has demonstrated pharmacists' potential through studies of how clinical pharmacists improve care for patients in many settings, especially for diabetes.

Officials with Ascensia Diabetes Care have announced that the Contour Next One Blood Glucose Monitoring System has received FDA 510(k) clearance.

Ingredient in aspirin combined with popular diabetes drug can turn off faulty protein that plays a key role in inflammatory diseases, such as rheumatoid arthritis.

An initiative that lowered copays for prescription drugs also lowered hospitalizations by 40%

Targeted personalized therapy in patients with diabetes can reduce the risk of developing cancer.

The FDA has approved Sanofi’s once-daily Soliqua 100/33 (insulin glargine and lixisenatide injection) for the treatment of adults with type 2 diabetes.

The FDA has approved the new drug application for Novo Nordisk’s Xultophy 100/3.6 as an adjunct to diet and exercise in adults with type 2 diabetes.

Type 2 diabetes patients struggle with high blood glucose levels that can damage nerves and blood vessels, factors that could trigger heart attacks.

Diabetes is a complex disease affecting 29.1 million individuals in the United States.

The holidays are just around the corner, but that’s not the only exciting thing about this time of year. ASHP’s 2016 Midyear Clinical Meeting is coming up, and Pharmacy Times is on site covering it.

New findings draw parallels between Alzheimer’s disease and diabetes.

Low health literacy, financial instability, and lack of social support promote poor adherence.

Top news of the day from across the healthcare landscape.

Poor medication adherence contributes to 125,000 deaths annually, causes up to half of all treatment failures, and costs the US healthcare system $100 billion each year.

Top news of the day from across the health care landscape.

Chronic diseases in the United States have a tremendous economic burden. Thirty-four percent of the economic burden of diabetes is attributed to the privately insured population.

Allergan plans to acquire Motus Therapeutics and relamorelin, an investigational drug to treat diabetic gastroparesis.

In a recent study, investigators found that the application of a topical gel that contains the gene heat shock protein 60 significantly increased wound healing in a mouse model of diabetes.

Beneficial results seen when switching to a HIV regimen including Odefsey.

Despite individuals with diabetes having a higher risk of developing serious eye diseases, more than half skip out on their annual eye exams.

Sight-saving eye exam skipped by diabetes patients, despite increased risk of serious eye diseases.

Top news of the day from across the health care landscape.

Although any amount of exercise is beneficial, exceeding the recommended level produces the most benefits for diabetes patients.

One of the most enduring lessons from my training in the care of geriatric patients is the following maxim: “Treat every new symptom like a (possible) drug adverse effect until proven otherwise.”

Inhibiting a specific protein can increase fat breakdown and prevent insulin resistance.

More than 86 million Americans over the age of 20 have prediabetes, 29 million Americans are diagnosed with diabetes, and another 8.1 million Americans are living with undiagnosed diabetes.

Patients with type 2 diabetes eventually need insulin therapy as their disease progresses. The American Diabetes Association recommends basal-only therapy initially, with the addition of bolus meal-time insulin as needed. However, recent research supports starting patients on combined basal-bolus regimens to control blood sugar regardless of added hypoglycemia risk.